Evidence map›Paper›PMID 41417435›Full record

ArticleDiscover oncology2025

Identification of NK cell marker genes based on single-cell sequencing to establish a prognostic signature in breast cancer.

Jiawei Zhang, Donghui Wang, Xiangmei He, Lan Hou, Juliang Zhang

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jiawei Zhang *Clinical Medicine, First Clinical Medical School, Nanchang University, Nanchang, Jiangxi, China.
Donghui Wang *Department of Thyriod & Breast Surgery, Xijing Hospital, West Changle Road, Xi'an, 710032, Shaanxi, China.
Xiangmei HeDepartment of Thyriod & Breast Surgery, Xijing Hospital, West Changle Road, Xi'an, 710032, Shaanxi, China.
Lan HouDepartment of Thyriod & Breast Surgery, Xijing Hospital, West Changle Road, Xi'an, 710032, Shaanxi, China. xyhoulan@126.com.
Juliang ZhangDepartment of Thyriod & Breast Surgery, Xijing Hospital, West Changle Road, Xi'an, 710032, Shaanxi, China. vascularzhang@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor-infiltrating natural killer (NK) cells are pivotal in modulating tumor progression, either by promoting or inhibiting neoplastic development. Nevertheless, the implications of NK cells in breast carcinoma remain inadequately understood. This investigation aimed to delineate the impact of NK cells on both the prognosis and the immune infiltration landscape in breast cancer.

methodsNK cell marker genes were identified using single-cell sequencing data from breast cancer available in the Gene Expression Omnibus (GEO) database. A prognostic model was constructed based on data from The Cancer Genome Atlas (TCGA) and subsequently validated with the GEO dataset. Disparities in immune cell infiltration between low-risk and high-risk cohorts, as stratified by the prognostic model, were examined. Additionally, genes differentially expressed between these cohorts were subjected to enrichment analysis.

resultsA total of 29 NK cell marker genes were identified through single-cell sequencing, and a prognostic model was subsequently developed using machine learning techniques based on the TCGA data. This model demonstrated robust predictive performance when applied to both TCGA and GEO datasets. Notably, a significant difference in immune infiltration was observed between the low-risk and high-risk groups. The findings were further validated through enrichment analysis.

conclusionsIn summary, we constructed a prognostic signature characterized by strong predictive performance, which has elucidated the critical role of NK cells in the pathogenesis of breast cancer. Furthermore, this model offers a predictive index and identifies a novel therapeutic target for the advancement of immunotherapeutic strategies in the clinical management of breast cancer patients.

Indexed as

Breast cancerCancer heterogeneityCellular infiltrationNatural killer cellPrognosisRisk scoreTumor microenvironment

Identifiers

PMID41417435
PMCPMC12830521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.